Immunology · 2017 · 46 citations · 31 references
Life SciencesImmunologyPathobiologyAutoimmunityCellular ImmunologyImmunoregulationAutoimmune Disease PathogenesisAutoimmune DiseasesCell-mediated ImmunityImmune ResponseImmunosuppressionSystemic Lupus ErythematosusAutoreactive T Cell ResponsesDendritic Cell Immune ToleranceDendritic Cell Tolerance InductionDendritic Cell Tolerogenic FunctionDendritic Cell TolerogenicityDendritic Cell-mediated Antigen PresentationTolerogenic Dendritic Cell TherapyTolerogenic Dendritic Cells
Summary Systemic lupus erythematosus ( SLE ) is an autoimmune disease with unrestrained T‐cell and B‐cell activity towards self‐antigens. Evidence shows that apoptotic cells (ApoCells) trigger an autoreactive response against nuclear antigens in susceptible individuals. In this study, we focus on generating and characterizing tolerogenic dendritic cells (tol DC s) to restore tolerance to ApoCells. Monocyte‐derived dendritic cells ( DC s) from healthy controls and patients with SLE were treated with dexamethasone and rosiglitazone to induce tol DC s. Autologous apoptotic lymphocytes generated by UV irradiation were given to tol DC s as a source of self‐antigens. Lipopolysaccharide ( LPS ) was used as a maturation stimulus to induce the expression of co‐stimulatory molecules and secretion of cytokines. Tol DC s generated from patients with SLE showed a reduced expression of co‐stimulatory molecules after LPS stimulation compared with mature DC s. The same phenomenon was observed in tol DC s treated with ApoCells and LPS . In addition, ApoCell‐loaded tol DC s stimulated with LPS secreted lower levels of interleukin‐6 ( IL ‐6) and IL ‐12p70 than mature DC s without differences in IL ‐10 secretion. The functionality of tol DC s was assessed by their capacity to prime allogeneic T cells. Tol DC s displayed suppressor properties as demonstrated by a significantly reduced capacity to induce allogeneic T‐cell proliferation and activation. ApoCell‐loaded tol DC s generated from SLE monocytes have a stable immature/tolerogenic phenotype that can modulate CD 4 + T‐cell activation. These properties make them suitable for an antigen‐specific immunotherapy for SLE .
31
Livia Casciola‐Rosen, Grant J. Anhalt, Antony Rosen · The Journal of Experimental Medicine · 1994 · 1.7K citations · Full text
Mortality in systemic lupus erythematosus
Sasha Bernatsky, J.‐F. Boivin, L. Joseph et al. · Arthritis & Rheumatism · 2006 · 1.2K citations · Full text
Social Sciences, Infectious Diseases, Clinical Epidemiology +16